Search
Prifinium
go.drugbank.com/drugs/DB13254ExperimentalIt may be useful for the treatment of irritable bowel syndrome [A175027].
Categories: Drugs for Functional Gastrointestinal DisordersTricaine
go.drugbank.com/drugs/DB11552ExperimentalVet approvedIt is also the only anesthetic licensed in the United States for use in fin fish that are intended for human consumption. … Tricaine (as tricaine methanesulfonate) is white powder used for anesthesia, sedation, or euthanasia of fish.
Prasugrel
go.drugbank.com/drugs/DB06209ApprovedInvestigationalPrasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary
Carbenicillin
go.drugbank.com/drugs/DB00578ApprovedBroad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseEDP1815
go.drugbank.com/drugs/DB16486InvestigationalEDP1815, was investigated in several clinical trials (NCT05066373, NCT05439941, NCT05682222, NCT03733353, NCT04603027, NCT04488575, NCT05121480, NCT04393246) to evaluate its safety and efficacy in conditions such as gastrointestinal beha...
Categories: Experimental Unapproved Treatments for COVID-19INCB13739
go.drugbank.com/drugs/DB05064InvestigationalINCB13739 is developed as a new treatment for type 2 diabetes.
Spirapril
go.drugbank.com/drugs/DB01348ApprovedInvestigationalSpirapril is an ACE inhibitor antihypertensive drug used to treat hypertension. Spirapril is converted to the active spiraprilat after administration. ACE inhibitors are used primarily in treatment of hypertension and congestive heart fa...
Ethylenediamine
go.drugbank.com/drugs/DB14189ApprovedEthylenediamine is an organic compound that is used as a building block for the production of many other chemical products.
Axatilimab
go.drugbank.com/drugs/DB16388ApprovedInvestigational[A264309] Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD. … [L51194] It is targeted against macrophage colony-stimulating factor 1 receptor (CSF-1R), causing a reduction in circulating levels of monocytes and macrophages responsible for the symptoms associated
Solabegron
go.drugbank.com/drugs/DB06190InvestigationalSolabegron (GW-427,353) is a selective β3 adrenoceptor agonist being developed for the treatment of overactive bladder and irritable bowel syndrome.
Categories: Drugs for Urinary Frequency and Incontinence